CVRx, Inc. (CVRX)
NASDAQ: CVRX · Real-Time Price · USD
7.85
-0.03 (-0.38%)
Aug 29, 2025, 4:00 PM - Market closed
Company Description
CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally.
The company offers Barostim, a neuromodulation device that enhance symptoms for patients with heart failure by delivering electrical pulses to baroreceptors.
It sells its products through direct sales force, sales agents, and independent distributors. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
CVRx, Inc.
| Country | United States |
| Founded | 2000 |
| IPO Date | Jun 30, 2021 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 206 |
| CEO | Kevin Hykes |
Contact Details
Address: 9201 West Broadway Avenue, Suite 650 Minneapolis, Minnesota 55445 United States | |
| Phone | 763 416 2840 |
| Website | cvrx.com |
Stock Details
| Ticker Symbol | CVRX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 0001235912 |
| CUSIP Number | 126638105 |
| ISIN Number | US1266381052 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Kevin Hykes | President, Chief Executive Officer and Director |
| Jared Oasheim | Chief Financial Officer |
| Robert Allen John | Chief Revenue Officer |
| Brent Binkowski | Chief Operating Officer |
| Jonelle R. Burnham | Vice President and General Counsel |
| Paul Verrastro | Chief Marketing and Strategy Officer |
| Tonya A. Austin SPHR | Chief Human Resources Officer |
| Dr. Philip B. Adamson M.D., M.Sc. | Chief Medical Officer |
| Bonnie Handke M.B.A., R.N. | Senior Vice President of Patient Access, Reimbursement, and Healthcare Economics |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 5, 2025 | 10-Q | Quarterly Report |
| Aug 4, 2025 | 8-K | Current Report |
| Jun 5, 2025 | 8-K | Current Report |
| May 23, 2025 | SD | Form - SD |
| May 9, 2025 | 10-Q | Quarterly Report |
| May 8, 2025 | 8-K | Current Report |
| Apr 23, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 23, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 7, 2025 | 8-K | Current Report |
| Feb 20, 2025 | SCHEDULE 13D/A | Filing |